Categories: DNANews

STRATA Skin Sciences to Report Fourth Quarter 2022 Financial Results on March 28, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

HORSHAM, Pa., March 14, 2023 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its fourth quarter 2022 financial results on Tuesday, March 28, 2023. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 PM EDT on the same day.

Tuesday, March 28, 2023, 4:30 PM EDT
Domestic: 877-269-7756
International: 201-689-7817
Conference ID: 13736453
Webcast: STRATA Skin Sciences Earnings Webcast

After the live webcast, the event will be archived for future reference on the STRATA Skin Sciences website at www.strataskinsciences.com under the investor relations section.

About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing and marketing innovative products for the in-office treatment of various dermatologic conditions such as psoriasis, vitiligo, and acne. Its products include the XTRAC® and Pharos® excimer lasers, VTRAC® lamp systems, and now the TheraClear®X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
sskn@cg.capital

Staff

Recent Posts

Harbinger Health Showcases Multi-Cancer Early Detection Performance in High-Risk Populations at ASCO 2025

Reflex blood-based multi-cancer early detection (MCED) test demonstrated clinically meaningful per-cancer Positive Predictive Value (PPV)…

6 hours ago

ImPact Biotech Presents Interim Analysis from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at ASCO 2025

– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial…

6 hours ago